Special Issue

Topic: Application of Liquid Biopsy for Prognostic Status of Cancers and Drug Response

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 30 Sep 2019

Guest Editor(s)

Dario Marchetti, Ph.D.
Professor, Division of Internal Medicine, Department of Molecular Medicine, Comprehensive Cancer Center, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA.

Special Issue Introduction

The vast majority of cancer deaths (>94%) is due to the development of metastatic disease with a considerable fraction of patients experiencing metastatic relapse within five years from primary tumor resection, despite not having any detectable metastasis at that time. Circulating tumor cells (CTCs) are shed from primary/metastatic tumors, circulate in the peripheral vasculature, disseminate to distant tissues, and extravasate by adapting to the new organ microenvironment, followed by tissue colonization generating metastasis. However, the complexities of the metastatic cascade in cancer patients and the elucidation of blood-based mechanisms underlying metastatic onset remain critical challenges. Because CTC dissemination mostly occurs through the blood, and only a minute proportion of CTCs can generate metastasis (metastasis-competent CTCs), investigating the biology of CTCs for biomarker discovery is critically relevant, which is one of the most promising areas of modern oncology research. Equally - beyond CTCs - there have been also many advances to detect and interrogate blood-based, tumor-specific biomarkers such as circulating tumor DNA (ctDNA), circulating exosomes and extracellular vesicles, tumor-educated platelets (TEPs), circulating cell-free microRNA (cfRNA), proteins and metabolites. The use of these analytes to obtain valuable diagnostic information from a blood/body fluids rather than from a tissue biopsy sample is broadly referred as "liquid biopsy". The development and application of "liquid biopsy" testing in the cancer patients is a novel and powerful diagnostic concept to monitor cancer progression directly, in real time, and non-invasively. However, many scientific, procedural, and technical limitations must be overcome before the promise of "liquid biopsy" can be fulfilled and be successfully and consistently implemented in the clinics. The objective of this Special Issue: "Application of Liquid Biopsy for Prognostic Status of Cancers and Drug Response" is to publish latest findings of liquid biopsy research and clinical application as prognostic indicator of therapy response. Contributions outlining discoveries in this area and the development/application of liquid biopsy testing either in pre-clinical or clinical models will include Reviews and Commentaries updating upon the relevance of "liquid biopsy" and analytes validity in the prevention or treatment of different tumor types. This Special Issue will also include Research articles presenting innovative advances impacting the field on all aspects and components of liquid biopsy. All manuscript submissions will be given a fair evaluation by undergoing rigorous peer-review, and will be published if considered acceptable for scientific divulgation.

Keywords

Liquid biopsy, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, extracellular vesicles (EVs), circulating cell-free microRNA (cfRNA), tumor-educated platelets (TEPs), circulating biomarkers

Submission Deadline

30 Sep 2019

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=296
Submission Deadline: 30 Sep 2019
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com
                  Chloe Yang, Assistant Editor, chloe@cdrjournal.com

Published Articles

Application of liquid biopsy for prognostic status of cancers and drug response

Open Access Editorial DOI: 10.20517/cdr.2020.96 2 Nov 2020
Views: Downloads:
Download PDF

Methods for extracellular vesicle isolation from cancer cells

Open Access Review DOI: 10.20517/cdr.2019.118 24 Apr 2020
Views: Downloads:
Download PDF

Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Open Access Original Article DOI: 10.20517/cdr.2019.116 16 Apr 2020
Views: Downloads:
Download PDF

Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy

Open Access Review DOI: 10.20517/cdr.2020.04 20 Mar 2020
Views: Downloads:
Download PDF

Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients

Open Access Review DOI: 10.20517/cdr.2019.90 18 Mar 2020
Views: Downloads:
Download PDF

Circulating tumor cells and drug history in primary breast cancer patients

Open Access Original Article DOI: 10.20517/cdr.2019.79 18 Mar 2020
Views: Downloads:
Download PDF

Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients

Open Access Original Article DOI: 10.20517/cdr.2019.73 18 Mar 2020
Views: Downloads:
Download PDF

The role of cell free DNA and liquid biopsies in haematological conditions

Open Access Review DOI: 10.20517/cdr.2019.93 12 Mar 2020
Views: Downloads:
Download PDF

Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells

Open Access Original Article DOI: 10.20517/cdr.2019.77 10 Mar 2020
Views: Downloads:
Download PDF

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Open Access Review DOI: 10.20517/cdr.2019.103 20 Feb 2020
Views: Downloads:
Download PDF

Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer

Open Access Perspective DOI: 10.20517/cdr.2019.99 18 Dec 2019
Views: Downloads:
Download PDF

Liquid biopsies in myeloid malignancies

Open Access Review DOI: 10.20517/cdr.2019.88 18 Dec 2019
Views: Downloads:
Download PDF

Components of the human-specific, p53-mediated “kill switch” tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation

Open Access Perspective DOI: 10.20517/cdr.2019.89 18 Dec 2019
Views: Downloads:
Download PDF

Liquid biopsy in metastatic breast cancer

Open Access Review DOI: 10.20517/cdr.2019.84 18 Dec 2019
Views: Downloads:
Download PDF

Exosomal lncRNAs: the newest promising liquid biopsy

Open Access Review DOI: 10.20517/cdr.2019.69 18 Dec 2019
Views: Downloads:
Download PDF

Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Open Access Case Report DOI: 10.20517/cdr.2019.53 18 Sep 2019
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/